DaShenLin Pharmaceutical Group CoSHSE:603233 95 EBITDA Margin % is 10.64% as of Mar. 2026, which is 6% below its 10-year median of 11.32. GuruFocus rates SHSE:603233 with a GF Score™ of 95/100 and a GF Value™ of ¥18.69 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 665 Healthcare Providers & Services companies, DaShenLin Pharmaceutical Group Co ranks worse than 58.95% on this metric.
DaShenLin Pharmaceutical Group Co (SHSE:603233) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
DaShenLin Pharmaceutical Group Co EBITDA Margin % Related Terms
DaShenLin Pharmaceutical Group Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DaShenLin Pharmaceutical Group Co EBITDA Margin % Chart
DaShenLin Pharmaceutical Group Co EBITDA Margin % Competitor Comparison
For the Pharmaceutical Retailers subindustry, DaShenLin Pharmaceutical Group Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DaShenLin Pharmaceutical Group Co EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, DaShenLin Pharmaceutical Group Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where DaShenLin Pharmaceutical Group Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DaShenLin Pharmaceutical Group Co (SHSE:603233) has a EBITDA Margin % of 10.64% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on DaShenLin Pharmaceutical Group Co and its competitors. This is near median its historical median of 11.32. Over the past decade, DaShenLin Pharmaceutical Group Co's EBITDA Margin % has ranged from 7.15 to 14.35. According to the industry distribution chart, DaShenLin Pharmaceutical Group Co ranks #392 out of 665 companies in the Healthcare Providers & Services industry, placing it in the top 58.9%.
Is DaShenLin Pharmaceutical Group Co's EBITDA Margin % too high?
DaShenLin Pharmaceutical Group Co's current EBITDA Margin % of 10.64% is near median its 10-year median of 11.32. Over the past 10 years, this metric has ranged from a low of 7.15 to a high of 14.35. The Healthcare Providers & Services industry median EBITDA Margin % is 10.24. DaShenLin Pharmaceutical Group Co's value of 10.64% is 3.9% above this industry median. Based on the distribution chart, DaShenLin Pharmaceutical Group Co ranks #392 out of 665 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, DaShenLin Pharmaceutical Group Co has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DaShenLin Pharmaceutical Group Co's EBITDA Margin % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, DaShenLin Pharmaceutical Group Co ranks #392 out of 665 companies for EBITDA Margin %. This places DaShenLin Pharmaceutical Group Co in the lower half of its industry. The industry median EBITDA Margin % is 10.24. DaShenLin Pharmaceutical Group Co's value of 10.64% is 3.9% above this benchmark. Historically, DaShenLin Pharmaceutical Group Co's own EBITDA Margin % has ranged from 7.15 to 14.35 over the past decade. While the company's 10-year median is 11.32 vs. the industry median of 10.24, DaShenLin Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.24, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DaShenLin Pharmaceutical Group Co's current EBITDA Margin % of 10.64% is 3.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on DaShenLin Pharmaceutical Group Co and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DaShenLin Pharmaceutical Group Co's current EBITDA Margin % is 10.64%, which is near median its own 10-year median of 11.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DaShenLin Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, DaShenLin Pharmaceutical Group Co (SHSE:603233) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥18.69, compared to a current price of ¥15.48 — trading 17.2% below its estimated fair value. The current EBITDA Margin % is 10.64%, which is near median its 10-year median of 11.32 and 3.9% above the Healthcare Providers & Services industry median of 10.24. DaShenLin Pharmaceutical Group Co's overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For DaShenLin Pharmaceutical Group Co (SHSE:603233), the current EBITDA Margin % is 10.64% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DaShenLin Pharmaceutical Group Co (SHSE:603233) Overvalued in 2026?
Based on GuruFocus' analysis, DaShenLin Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of ¥15.48 is trading 17.2% below its estimated GF Value™ of ¥18.69.
GuruFocus considers DaShenLin Pharmaceutical Group Co to be Modestly Undervalued.
Key valuation signals for SHSE:603233:
EBITDA Margin %: 10.64% (near median its 10-year median of 11.32)
GF Value™: ¥18.69 vs. price of ¥15.48 (17.2% below fair value)
Industry Position: 3.9% above the Healthcare Providers & Services median (#392 of 665)
No single metric tells the full story. See the SHSE:603233 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DaShenLin Pharmaceutical Group Co Business Description
DaShenLin Pharmaceutical Group Co Ltd is engaged in the pharmaceutical manufacturing, retail, and wholesale business. The company is based on the development of the pharmacy chain. It primarily offers Chinese herbal medicine such as antibiotics and biochemical drugs. The business activities are geographically carried out through China.
95GF Score
Get the complete analysis for SHSE:603233
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603233 has been successfully added to your 
